Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Becton, Dickinson and Co. (BDX): SWOT

Becton, Dickinson and Co. (NYSE:BDX)‘s second-quarter earnings report is a good reason to give the company a onceover with a SWOT — Strengths, Weaknesses, Opportunities, and Threats — analysis. Becton met analysts’ expectations for revenue and earnings beat estimates. The market liked the report, injecting more than $2.50 to the share price and send sending it to a new high.

Here’s a business snapshot.

Company Name Becton Dickinson and Co. (NYSE: BDX )
One sentence statement of operations Becton Dickinson manufactures and sells a broad range of medical supplies, devices, laboratory equipment and diagnostic products.
Recent price $96.16
Market Cap $18.65 billion
Forward P/E (next 12 months’ EPS) 15.4
Dividend Yield 2.1% with 25% payout ratio

Source: Yahoo! Finance and Becton Dickinson home page.

Strengths:

  • Becton, Dickinson and Co. (NYSE:BDX) is a member of the S&P 500 Dividend Aristocrats — S&P 500 companies that have raised their dividend every year for at least 25 years. In Becton’s case, the string is 41 years.
  • The company’s share repurchase plan is actually reducing shares outstanding.
  • Company guidance for FY2013 revenue and earnings were both raised.

Weaknesses:

  • The Affordable Care Act is starting to ding earnings. This quarter, new medical device taxes took five cents per share out of the bottom line. The tax is expected to cost Becton, Dickinson and Co. (NYSE:BDX) $45 million this fiscal year.
  • Gross margin and operating margin are down slightly compared to the year-ago quarter.

Opportunities:

  • Emerging markets operations account for just under 25% of revenues and have a solid double-digit growth rate.
  • The acquisition of Cato Software Solutions opens new business lines in medical safety and error prevention.
  • Becton has launched a number of new products recently, such as prefilled injectables, and has several new products in the pipeline.  Becton, Dickinson and Co. (NYSE:BDX) has a geographically diverse business base with more than half its revenues coming from outside the U.S.

Threats:

  • Health care is a hot topic in politics and taxes. Product approvals or regulations can pose a threat to operations or profitability.
  • That geographically diverse base brings currency exchange rate risk along with it. Currency exchange clipped 1.5% off year-over-year earnings growth last quarter.

Becton, Dickinson and Co. (NYSE:BDX)Becton, Dickinson and Co. (NYSE:BDX) isn’t an exciting stock — and that’s a good thing. Revenue growth of 3%-4% and earnings growth rates of 6% or so aren’t going to make headlines. But combine those moderate growth rates with a low payout ratio and a business with demand in every part of the economic cycle, and Becton is positioned to keep making those annual dividend hikes income investors count on. I own shares in Becton, Dickinson and Co. (NYSE:BDX) and believe it’s an excellent candidate for investors looking for steady, growing income.

The article Becton Dickinson: Strengths, Weaknesses, Opportunities, and Threats originally appeared on Fool.com.

Russ Krull owns shares of Becton Dickinson. The Motley Fool recommends Becton Dickinson.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Loading Comments...